Glioma Panel MGMT IDH1/2 FISH 1p19q: Comprehensive Brain Tumor Genetic Analysis
Understanding Glioma Genetic Testing
The Glioma Panel MGMT IDH1/2 FISH 1p19q represents a cutting-edge molecular diagnostic approach specifically designed for comprehensive brain tumor analysis. This sophisticated genetic panel provides clinicians with essential information for accurate glioma classification, prognosis assessment, and treatment planning. By examining multiple genetic markers simultaneously, this test offers a complete molecular profile that guides personalized therapeutic decisions for patients with brain tumors.
What This Test Measures and Detects
Our comprehensive glioma panel analyzes three critical genetic components that are fundamental to modern neuro-oncology:
MGMT Promoter Methylation Status
- Evaluates methylation patterns in the O6-methylguanine-DNA methyltransferase gene
- Determines sensitivity to temozolomide chemotherapy
- Provides prognostic information for treatment response
IDH1 and IDH2 Mutations
- Identifies specific mutations in isocitrate dehydrogenase genes 1 and 2
- Helps distinguish between primary and secondary glioblastomas
- Provides important prognostic information
- Informs tumor classification according to WHO guidelines
1p/19q Chromosomal Codeletion Analysis
- Detects combined deletion of chromosomes 1p and 19q
- Characteristic of oligodendrogliomas
- Predicts better response to chemotherapy and radiation
- Associated with improved overall survival
Who Should Consider This Test
This comprehensive genetic panel is recommended for patients experiencing:
- Newly diagnosed brain tumors suspected to be gliomas
- Recurrent brain tumors requiring updated molecular profiling
- Unexplained neurological symptoms with imaging suggestive of glioma
- Patients being evaluated for targeted therapy options
- Individuals requiring precise tumor classification for treatment planning
- Patients with family history of brain tumors or genetic syndromes
Key Benefits of Glioma Genetic Testing
Personalized Treatment Planning
Our comprehensive panel provides critical information that directly influences treatment decisions, helping oncologists select the most effective therapies based on your tumor’s genetic profile.
Accurate Prognostic Assessment
By analyzing multiple genetic markers, this test offers valuable insights into disease progression and expected outcomes, allowing for more informed discussions about treatment goals and expectations.
Targeted Therapy Selection
The genetic information obtained helps identify patients who may benefit from specific targeted therapies, potentially improving treatment efficacy while minimizing unnecessary side effects.
Comprehensive Molecular Profiling
Unlike single-marker tests, our panel provides a complete molecular picture of your glioma, ensuring no critical genetic information is overlooked in your diagnostic evaluation.
Understanding Your Test Results
Your test results will provide detailed information about three key genetic aspects of your glioma:
MGMT Methylation Interpretation
- Methylated: Indicates potential sensitivity to temozolomide chemotherapy and generally better prognosis
- Unmethylated: Suggests reduced response to standard chemotherapy, requiring alternative treatment approaches
IDH Mutation Status
- IDH-mutant: Typically associated with better prognosis and specific treatment considerations
- IDH-wildtype: May indicate more aggressive tumor behavior requiring different management strategies
1p/19q Codeletion Analysis
- Codeleted: Characteristic of oligodendrogliomas with better treatment response and survival outcomes
- Intact: Suggests different glioma subtypes requiring alternative treatment approaches
Your healthcare provider will discuss these results in detail and explain how they impact your specific treatment plan and prognosis.
Test Pricing and Information
| Test Name | Discount Price | Regular Price |
|---|---|---|
| Glioma Panel MGMT IDH1/2 FISH 1p19q | $900 USD | $1200 USD |
Additional Test Details
- Turnaround Time: 2-3 weeks
- Sample Type: Paraffin-embedded tumor tissue blocks
- Testing Methods: MLPA + FISH + Sanger Sequencing
- Prescription Requirements: Doctor’s prescription required (not applicable for surgery, pregnancy, or international travel cases)
Nationwide Testing Availability
We have testing facilities conveniently located across the United States, serving patients in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, Austin, Jacksonville, Fort Worth, Columbus, San Francisco, and many other cities. Our network ensures accessible genetic testing services regardless of your location.
Take Control of Your Brain Health Today
Don’t leave your brain tumor diagnosis to chance. Our comprehensive Glioma Panel provides the critical genetic information needed for informed treatment decisions and personalized care. With our advanced testing capabilities and nationwide availability, you can access state-of-the-art genetic analysis that can make a significant difference in your treatment journey.
Ready to get started? Call or WhatsApp us today at +1(267) 388-9828 to schedule your test or speak with our genetic counseling team. Take the first step toward understanding your glioma at the molecular level and optimizing your treatment strategy.
